The Right Care Alliance strongly opposes the recent approval by the FDA of aducanumab (Aduhelm), a drug marketed by Biogen for Alzheimer’s disease, and has issued an official statement calling for its withdrawal.
The Right Care Alliance strongly opposes the recent approval by the FDA of aducanumab (Aduhelm), a drug marketed by Biogen for Alzheimer’s disease, and has issued an official statement calling for its withdrawal.